참고문헌 (30)

1. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden？of adults with major depressive disorder in the United States (2005？and 2010). J Clin Psychiatry 2015;76(2):155-62. 

   상세보기

2. Compton WM, Conway KP, Stinson FS, et al. Changes in the？prevalence of major depression and comorbid substance use？disorders in the United States between 1991-1992 and 2001-2002.？Am J Psychiatry 2006;163(12):2141-7. 

3. Association AP. Practice guidelines for the treatment of patients with？major depressive disorder, 3rd edition. Available from https://？psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/？guidelines/mdd.pdf. Accessed December 20, 2022. 

4. Seo JS, Bahk WM, Woo YS, et al. Korean Medication Algorithm？for Depressive Disorder 2021, Fourth Revision: An Executive？Summary. Clin Psychopharmacol Neurosci 2021;19(4):751-72. 

   상세보기

5. Prukkanone B, Vos T, Burgess P, et al. Adherence to antidepressant？therapy for major depressive patients in a psychiatric hospital in？Thailand. BMC Psychiatry 2010;10:64. 

   상세보기

6. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to？antidepressant treatment in patients with depression: a chart review.？BMC Psychiatry 2009;9:38. 

   상세보기

7. Keyloun KR, Hansen RN, Hepp Z, et al. Adherence and Persistence？Across Antidepressant Therapeutic Classes: A Retrospective Claims？Analysis Among Insured US Patients with Major Depressive？Disorder (MDD). CNS Drugs 2017;31(5):421-32. 

   상세보기

8. Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial？response, and failure to achieve remission: humanistic and cost？burden in major depressive disorder. Depress Anxiety 2009;26(1):83-97. 

   상세보기

9. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence？to antidepressant treatment guidelines on relapse and recurrence of？depression. Arch Gen Psychiatry 1998;55(12):1128-32. 

   상세보기

10. Renom-Guiteras A, Meyer G, Thurmann PA. The EU(7)-PIM list: a？list of potentially inappropriate medications for older people？consented by experts from seven European countries. Eur J Clin？Pharmacol 2015;71(7):861-75. 

    상세보기

11. Olsson J, Bergman A, Carlsten A, et al. Quality of drug prescribing？in elderly people in nursing homes and special care units for？dementia: a cross-sectional computerized pharmacy register analysis.？Clin Drug Investig 2010;30(5):289-300. 

    상세보기

12. Cramer JA, Roy A, Burrell A, et al. Medication compliance and？persistence: terminology and definitions. Value Health 2008;11(1):44-7. 

    상세보기

13. Hess LM, Raebel MA, Conner DA, et al. Measurement of？adherence in pharmacy administrative databases: a proposal for？standard definitions and preferred measures. Ann Pharmacother？2006;40(7-8):1280-88. 

14. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent？adherence to multiple related medications. Am J Manag Care？2009;15(7):457-64. 

15. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of？medication adherence and persistence using automated databases.？Pharmacoepidemiol Drug Saf 2006;15(8):565-74. 

    상세보기

16. Malo S, Aguilar-Palacio I, Feja C, et al. Different approaches to the？assessment of adherence and persistence with cardiovasculardisease preventive medications. Curr Med Res Opin 2017;33(7):？1329-36. 

    상세보기

17. Forbes CA, Deshpande S, Sorio-Vilela F, et al. A systematic？literature review comparing methods for the measurement of patient？persistence and adherence. Curr Med Res Opin 2018;34(9):1613-25. 

    상세보기

18. Baumgartner PC, Haynes RB, Hersberger KE, et al. A Systematic？Review of Medication Adherence Thresholds Dependent of Clinical？Outcomes. Front Pharmacol 2018;9:1290. 

    상세보기

19. Liu X, Tepper PG, Able SL. Adherence and persistence with？duloxetine and hospital utilization in patients with major depressive？disorder. Int Clin Psychopharmacol 2011;26(3):173-80. 

20. Mantarro S, Capogrosso-Sansone A, Tuccori M, et al. Allopurinol？adherence among patients with gout: an Italian general practice？database study. Int J Clin Pract 2015;69(7):757-65. 

    상세보기

21. Chang TE, Park S, Yang Q, et al. Association between long-term？adherence to class-I recommended medications and risk for？potentially preventable heart failure hospitalizations among younger？adults. PLoS One 2019;14(9):e0222868. 

    상세보기

22. Hwang JE, Song I, Lee EK, et al. Prevalence and predictors of？tricyclic antidepressant use among elderly Koreans in primary-care？and specialty clinics. Int J Clin Pharmacol Ther 2018;56(5):224-30. 

    상세보기

23. Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the？role of pharmacodynamics and pharmacokinetics in drug safety.？Expert Opin Drug Metab Toxicol 2015;11(6):883-92. 

24. Hung CI. Factors predicting adherence to antidepressant treatment.？Curr Opin Psychiatry 2014;27(5):344-9. 

    상세보기

25. Jeon-Slaughter H. Economic factors in of patients' nonadherence to？antidepressant treatment. Soc Psychiatry Psychiatr Epidemiol？2012;47(12):1985-98. 

26. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review？of efficacy, safety and tolerability with a focus on cognitive？symptoms in major depressive disorder. Expert Opin Drug Saf？2015;14(8):1291-304. 

27. De Diego-Adelino J, Crespo JM, Mora F, et al. Vortioxetine in major？depressive disorder: from mechanisms of action to clinical studies.？An updated review. Expert Opin Drug Saf 2022;21(5):673-90. 

28. Ta JT, Sullivan SD, Tung A, et al. Health care resource utilization？and costs associated with nonadherence and nonpersistence to？antidepressants in major depressive disorder. J Manag Care Spec？Pharm 2021;27(2):223-39. 

    상세보기

29. Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on？cognitive performance in working patients with major depressive？disorder: A short-term, randomized, double-blind, exploratory study.？J Affect Disord 2018;229:421-8. 

30. Thase ME, Danchenko N, Brignone M, et al. Comparative？evaluation of vortioxetine as a switch therapy in patients with major？depressive disorder. Eur Neuropsychopharmacol 2017;27(8):773-81.？ 

    상세보기

저자의 다른 논문 :

이경주 (3)